Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness.
The results from an internationally recognized clinical phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy.
The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas.